Tumor-specific CD4+ T cells can support therapeutic effects by maintaining effector CD8+ T cells, which are important to reduce the exhaustion of CD8+ T cells mediated by PD-1 and TRAIL-mediated apoptosis during initial tumor elimination (Church et al. 2014). The gene discussed is TNFSF10; the disease is neoplasm.